Any feedback?
Literature summary for 1.6.5.2 extracted from
- Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia (2008), Leuk. Res., 33, 74-81.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | trend toward lower drug response in patients with the NQO1 null genotype. Inhibiting NQO1 activity decreases p53 levels and drug induced apoptosis in chronic lymphocytic leukemia cells. NQO1 polymorphism may be a risk factor for chronic lymphocytic leukemia especially in males, and a predictor of response to chemotherapy | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| dicoumarol | - |
Homo sapiens |  |
| ES936 | - |
Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| HCT-116 cell | - |
Homo sapiens | - |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| NAD(P)H:quinoneoxidoreductase 1 | - |
Homo sapiens |
| NQO1 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
